Znanje i stavovi farmaceuta o biološkim i biosličnim lekovima: pregled literature

  • Marija Trajculeski Univerzitet „Goce Delčev“, Fakultet medicinskih nauka, Odsek za farmaciju, Štip, Severna Makedonija; Agencija za lekove i medicinska sredstva, Skoplje, Severna Makedonija
  • Zorica Naumovska Univerzitet „Sveti Kirilo i Metodije“ u Skoplju, Farmaceutski fakultet, Skoplje, Severna Makedonija
  • Darinka Gjorgieva Ackova Univerzitet „Goce Delčev“, Fakultet medicinskih nauka, Odsek za farmaciju, Štip, Severna Makedonija
  • Marija Darkovska Serafimovska Univerzitet „Goce Delčev“, Fakultet medicinskih nauka, Odsek za farmaciju, Štip, Severna Makedonija
  • Biljana Lazarova Univerzitet „Goce Delčev“, Fakultet medicinskih nauka, Odsek za farmaciju, Štip, Severna Makedonija; Bolnička apoteka, Klinička bolnica, Štip, Severna Makedonija
  • Katarina Smilkov Univerzitet „Goce Delčev“, Fakultet medicinskih nauka, Odsek za farmaciju, Štip, Severna Makedonija
DOI: https://doi.org/10.5937/arhfarm75-62932
Ključne reči: biološki lekovi, biosimilari, farmaceuti, znanje, stavovi

Sažetak


Napredak u biološkim terapijama postao je ključan za lečenje i akutnih i hroničnih bolesti. Pored toga, sve veće prisustvo biosličnih lekova predstavlja značajne mogućnosti za smanjenje troškova zdravstvene zaštite i proširenje pristupa pacijenata osnovnim biološkim tretmanima. Farmaceuti, kao deo zdravstvenog sistema, igraju važnu ulogu u upotrebi ove grupe lekova. Svrha ovog pregleda literature je da se ispitaju postojeća istraživanja o znanju i stavovima farmaceuta prema originalnim biološkim lekovima i biosimilarima, kao i da se proceni potreba za daljim obrazovnim inicijativama u ovoj oblasti.

Digitalna pretraga literature sprovedena je putem baza podataka časopisa, kao što su PubMed i Scopus, koristeći odabrane termine za pretragu i primenjujući kriterijume za uključivanje koji odgovaraju cilju istraživanja. Većina studija koje su predmet evaluacije sprovedene su u obliku kratkih anketa, što otkriva da je većina farmaceuta upoznata sa biološkim i biosličnim lekovima, međutim, njihovo izmereno znanje je bilo manje opsežno od njihovog samoprocenjenog znanja. Znanje i stavovi farmaceuta prema biološkim lekovima pokazuju velike varijacije.

Nedovoljno kliničkog iskustva i potreba za dodatnom edukacijom identifikovani su kao preduslovi za veće uključivanje originalnih bioloških i biosličnih lekova u kliničku praksu.

Reference

Assessing the impact of promotion and advertising regulations on biosimilar uptake [Internet]. OECD Publishing; 2025 [cited 2026 Apr 14]. Available from: https://www.oecd.org/content/dam/oecd/en/publications/reports/2025/12/assessing-the-impact-of-promotion-and-advertising-regulations-on-biosimilar-uptake_27d29388/c69f54b2-en.pdf

Biosimilar medicines: Overview [Internet]. European Medicines Agency (EMA); 2017 [cited 2026 Apr 15]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview.

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use [Internet]. EUR-Lex; 2001 [cited 2026 Apr 15]. Available from: http://data.europa.eu/eli/dir/2001/83/oj.

The impact of biosimilar competition in Europe [Internet]. IQVIA Institute for Human Data Science; 2018 [cited 2026 Apr 15]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/2026/iqvia-the-impact-of-biosimilar-competition-in-europe-2026-01-26-forweb.pdf

Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, TRS No 977 [Internet]. WHO; 2010 [cited 2026 Apr 15]. Available from: https://www.who.int/publications/m/item/sbp-trs-977-Annex-2.

Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discov. 2012;11(7):527–40. doi: 10.1038/nrd3746.

Guideline on Immunogenicity assessment of therapeutic proteins [Internet]. EMA; 2017 [cited 2026 Apr 14]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.

Product- or Population-Specific Considerations II: Biological medicinal products, GVP [Internet]. EMA; 2016 [cited 2026 Apr 14]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-gvp-product-or-population-specific-considerations-ii-biological-medicinal-products_en.pdf.

Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017;77(6):671–7. doi: 10.1007/s40265-017-0717-1.

Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502–9. doi: 10.1016/S1470-2045(16)30374-6.

Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, et al. Biosimilars: what clinicians should know. Blood. 2012;120(26):5111–7. doi: 10.1182/blood-2012-04-425744.

Hung A, Vu Q, Mostovoy L. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? J Manag Care Spec Pharm. 2017;23(12):1234–44. doi: 10.18553/jmcp.2017.23.12.1234.

Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review. J Manag Care Spec Pharm. 2019;25(1):102–12. doi: 10.18553/jmcp.2019.25.1.102.

Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, et al. Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther. 2016;33(12):2160–72. doi: 10.1007/s12325-016-0431-5.

Oskouei ST, Kusmierczyk AR. Biosimilar Uptake: The Importance of Healthcare Provider Education. Pharm Med. 2021;35(4):215–24. doi: 10.1007/s40290-021-00396-7.

Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, et al. Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts. BioMed Res Int. 2018;2018:1–9. doi: 10.1155/2018/9597362.

Oqal M, Hijazi B, Alqudah A, Al-Smadi A, A Almomani B, Alnajjar R, et al. Awareness and Knowledge of Pharmacists toward Biosimilar Medicines: A Survey in Jordan. Int J Clin Pract. 2022;2022(1):8080308. doi: 10.1155/2022/8080308.

Sidikou, O. CP-108 Biosimilars: What do clinicians actually think? Eur J Hosp Pharm. 2016;23:A47–8. doi: 10.1136/ejhpharm.

Trajchuleski M, Naumovska Z, Ackova DG, Serafimovska MD, Lazarova B, Smilkov K. Medical specialists' knowledge and perceptions of biologicals and biosimilars: a literature review. Acad Med J. 2025;5(3):1–9.

Pasina, LNA. A survey among hospital specialists and pharmacists about biosimilars. Eur J Intern Med. 2016;35:e31–3.

Adé A, Bourdon O, Bussières JF. A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France. Ann Pharm Fr. 2017;75(4):267–75. doi: 10.1016/j.pharma.2017.01.003.

O’Callaghan J, Bermingham M, Leonard M, Hallinan F, Morris JM, Moore U, et al. Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol. 2017;88:252–61. doi: 10.1016/j.yrtph.2017.06.013.

Beck M, Michel B, Rybarczyk-Vigouret MC, Levêque D, Sordet C, Sibilia J, et al. Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. BioDrugs. 2016;30(6):585–92. doi: 10.1007/s40259-016-0202-5.

Cook JW, McGrath MK, Dixon MD, Switchenko JM, Harvey RD, Pentz RD. Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing. Ther Adv Med Oncol. 2019;11:1758835918818335. doi: 10.1177/1758835918818335.

Pawłowska I, Pawłowski L, Krzyżaniak N, Kocić I. Perspectives of Hospital Pharmacists Towards Biosimilar Medicines: A Survey of Polish Pharmacy Practice in General Hospitals. BioDrugs. 2019;33(2):183–91. doi: 10.1007/s40259-019-00341-w.

Messner K, Eickhoff C, Schulz M, Allemann SS, Arnet I. Knowledge and attitudes of German and Swiss community pharmacists towards biologicals and biosimilars – a prospective survey before and after the COVID-19 pandemic. BMC Health Serv Res. 2023;23(1):1432. doi: 10.1186/s12913-023-10475-x.

Arnet I, Verbeek M, Almarsdóttir Anna B, Barbier L, Clifford R, Eickhoff C, et al. Community pharmacists’ preparedness for substituting biologics and dispensing biosimilars – Lessons learned from a multinational survey. Explor Res Clin Soc Pharm. 2021;4:100084. doi: 10.1016/j.rcsop.2021.100084.

Poon SYK, Hsu JC, Ko Y, Chiang SC. Assessing Knowledge and Attitude of Healthcare Professionals on Biosimilars: A National Survey for Pharmacists and Physicians in Taiwan. Healthcare. 2021;9(11):1600. doi: 10.3390/healthcare9111600.

Hu Y, Song Z, Jiang D, Zhuo L, Cheng Y, Zhao R. Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey. Front Pharmacol. 2022;13:876503. doi: 10.3389/fphar.2022.876503.

Stevenson JG, McCabe D, McGrath M, McBride A. Pharmacist biosimilar survey reveals knowledge gaps. J Am Pharm Assoc. 2023;63(2):529–537. doi: 10.1016/j.japh.2022.11.001.

Giavatto C, Mourani J, Fitzpatrick C, Hardin B, Skrtic A, Evans A, et al. Biosimilar perceptions among autoimmune prescribers and pharmacists in health system specialty pharmacy. J Manag Care Spec Pharm. 2024;30(2):175–82. doi: 10.18553/jmcp.2024.30.2.175.

Jarab AS, Al-Qerem W, Alzoubi KH, Abu Heshmeh SR, Al Hamarneh YN, Alefishat E, et al. Understanding Community Pharmacists’ Knowledge, Attitudes, and Practices Regarding Biosimilar Drugs: A Cross‐Sectional Survey. Int J Clin Pract. 2025;2025(1):2248512. doi: 10.1155/ijcp/2248512.

Ling YL, Gentile D, Kotomale A, Sharpe JA, Geli D, Gruben D, et al. Real-world familiarity with US biosimilar regulatory guidelines and interchangeability state laws among pharmacists and physicians treating immunological disorders. J Manag Care Spec Pharm. 2025;31(6):552–64. doi: 10.18553/jmcp.2025.31.6.552.

Shakeel S, Hassali MA, Rehman H, Rehman AU, Muneswarao J. Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists. Int J Gen Med. 2020;13:1075–82. doi: 10.2147/IJGM.S266545.

Objavljeno
2026/04/29
Broj časopisa
Vol. 76 Br. Notebook 2 (2026)
Rubrika
Pregledni (Revijalni) rad
Autori koji objavljuju u ovom časopisu pristaju na sledeće uslove:

  1. Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga "Creative Commons Attribution licencom" koja omogućava drugima da dele rad, uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.

  2. Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju članka objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je članak izvorno objavljen u ovom časopisu.

  3. Autorima je dozvoljeno i podstiču se da postave objavljeni članak onlajn (npr. u institucionalni repozitorijum ili na svoju internet stranicu) pre ili tokom postupka prijave rukopisa, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog članka (Vidi Efekti otvorenog pristupa).